Research progress in the application of mineralocorticoid receptor antagonists in the treatment of diabetic kidney disease
The excessive activation of the mineralocorticoid receptor(MR)is closely linked to the development and progression of diabetic kidney disease(DKD).Mineralocorticoid receptor antagonists(MRAs)play a protective role in DKD by inhibiting MR,which lead to anti-inflammatory and anti-fibrotic effects,ultimately improving organ damage.Steroidal MRAs have a well-established mode of action,but their use is limited due to adverse effects such as hyperkalemia and hormonal disturbances.In recent years,non-steroidal MRAs have emerged as a promising option for DKD treatment,demonstrating significant efficacy along with greater selectivity and improved safety profiles.They are considered a novel therapeutic approach to slow down the progression of DKD.This paper offers a comprehensive review of the mechanisms and clinical research advancements related to MRAs in the treatment of DKD,aiming to provide valuable insights for clinical practice.
万方数据
维普
